Document Detail


The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia.
MedLine Citation:
PMID:  16906592     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The most frequent autoimmune complication in chronic lymphocytic leukemia (CLL) is autoimmune hemolytic anemia (AIHA). There are various treatment modalities; however, there is not much experience with the use of the chimeric anti-CD20 monoclonal antibody rituximab in the autoimmune complications of CLL. Here, we present our patient with CLL and AIHA whose AIHA was unresponsive to various treatment modalities. The administration of 375 mg/m(2)/day rituximab weekly for four cycles halted hemolysis and resulted in resolution of the patient's anemia. One year after therapy, the patient is well with a normal blood count. Rituximab might be preferred over other treatment modalities in the autoimmune complications of CLL because it is effective and has fewer side effects than other therapies.
Authors:
Gülsüm Emel Pamuk; Burhan Turgut; Muzaffer Demir; Fatma Tezcan; Ozden Vural
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  American journal of hematology     Volume:  81     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-14     Completed Date:  2007-10-09     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  631-3     Citation Subset:  IM    
Affiliation:
Division of Hematology, Trakya University Medical Faculty, Edirne, Turkey. gepamuk@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Anemia, Hemolytic, Autoimmune / complications*,  diagnosis,  drug therapy*
Antibodies, Monoclonal / administration & dosage*
Follow-Up Studies
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications*
Male
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hypothermia during the infusion of cryopreserved autologous peripheral stem cell causes electrocardi...
Next Document:  Pulmonary alveolar proteinosis with myeloproliferative syndrome with myelodysplasia: bronchoalveolar...